CDK7-IN-26
Product Specifications
UNSPSC Description
CDK7-IN-26 (compound 36) is an orally active CDK7 inhibitor (IC50: 7.4 nM). CDK7-IN-26 potently inhibits the growth of triple-negative breast cancer (TNBC) cell line-derived xenograft (CDX) tumors in vivo and inhibits MDA-MB-453 cells in vitro with an IC50 of 0.15 μM[1].
Target Antigen
CDK
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
cancer
Assay Protocol
https://www.medchemexpress.com/cdk7-in-26.html
Solubility
10 mM in DMSO
Smiles
O=P(C)(C1=C(C=CC2=C1NC=C2C3=NC(N[C@H]4C[C@H](F)CNC4)=NC5=C3SC=C5)C#N)C
Molecular Weight
468.49
References & Citations
[1]Zhang H et al. Discovery and optimization of thieno [3, 2-d] pyrimidine derivatives as highly selective inhibitors of cyclin-dependent kinase 7[J]. European Journal of Medicinal Chemistry, 2023: 115955.
Shipping Conditions
Room temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-157210/CDK7-IN-26-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-157210/
Clinical Information
No Development Reported
CAS Number
3024545-79-4
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
